Measurement of selected androgens using liquid chromatography-tandem mass spectrometry in reproductive-age women with Type 1 diabetes by Gunness, A. et al.
 
 
University of Birmingham
Measurement of selected androgens using liquid
chromatography-tandem mass spectrometry in
reproductive-age women with Type 1 diabetes
Gunness, A.; Pazderska, A.; Ahmed, M.; McGowan, A.; Phelan, N.; Boran, G.; Taylor,
Angela; O'Reilly, Michael; Arlt, Wiebke; Moore, K.; Behan, L. A.; Sherlock, M.; Gibney, J.
DOI:
10.1093/humrep/dey243
License:
Other (please specify with Rights Statement)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Gunness, A, Pazderska, A, Ahmed, M, McGowan, A, Phelan, N, Boran, G, Taylor, A, O'Reilly, M, Arlt, W, Moore,
K, Behan, LA, Sherlock, M & Gibney, J 2018, 'Measurement of selected androgens using liquid chromatography-
tandem mass spectrometry in reproductive-age women with Type 1 diabetes', Human Reproduction.
https://doi.org/10.1093/humrep/dey243
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
This is a pre-copyedited, author-produced PDF of an article accepted for publication in Human Reproduction following peer review. The
version of record A Gunness, A Pazderska, M Ahmed, A McGowan, N Phelan, G Boran, A E Taylor, M W O’Reilly, W Arlt, K Moore, L A
Behan, M Sherlock, J Gibney; Measurement of selected androgens using liquid chromatography–tandem mass spectrometry in
reproductive-age women with Type 1 diabetes, Human Reproduction, , dey243, https://doi.org/10.1093/humrep/dey243 is available online at:
10.1093/humrep/dey243
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
  
1 
1 
Measurement of selected androgens using liquid chromatography-tandem mass 1 
spectrometry in reproductive-age women with Type 1 diabetes. 2 
 3 
Running Title: Androgens measured by LC-MS/ MS in women with T1D  4 
 5 
A Gunness1, A Pazderska 1, M Ahmed 1, A. McGowan1, N Phelan1, G Boran 2, A E Taylor3, M W 6 
O’Reilly3, W Arlt3, K Moore1,LA Behan1,M Sherlock1 and J Gibney*1 7 
 8 
1Department of Endocrinology and 2Clinical Chemistry, Adelaide and Meath Hospital, Tallaght, 9 
Dublin 24, Republic of Ireland .3Institute of Metabolism and Systems Research (IMSR), 10 
University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. 11 
 12 
 13 
Correspondence address: James.Gibney@amnch.ie 14 
  
2 
2 
Abstract  15 
Study question: What information does androgen profiling using liquid chromatography tandem 16 
mass spectrometry (LC-MS/MS) provide in reproductive-age women with Type 1 diabetes 17 
(T1D)? 18 
Summary answer:  In T1D women, androstenedione proved most useful of the measured 19 
androgens in differentiating subgroups based on clinical phenotypes of hyperandrogenism (HA) 20 
and polycystic ovary syndrome (PCOS). 21 
What is known already: The prevalence of HA and PCOS are increased in women with T1D. 22 
These observations are based on measurement of serum androgens using immunoassays, to-23 
date no studies using LC-MS/MS have been reported in reproductive-age women with T1D. 24 
Study design, size, duration: This was a cross-sectional study with recruitment of 3 groups of 25 
reproductive-age women: women with T1D (n=87), non-diabetic women with (N=97) and without 26 
PCOS (N=101). 27 
Participants/materials, setting, methods: Using LC-MS/MS, we aimed to characterize 28 
androgen profiles and PCOS status in women with T1D, and interpret findings in relation to 29 
cohorts of non-diabetic women with and without PCOS. 30 
Main results and the role of chance:  Compared to non-diabetic women, 31 
dehydroepiandrosterone / dehydroepiandrosterone sulphate (DHEA/ DHEAS) ratio was lower 32 
(p<0.05) in women with T1D. Testosterone levels were greater in T1D women with clinical HA 33 
and anovulation compared to those without clinical HA and with regular cycles, while 34 
androstenedione levels were greater in T1D women with HA and anovulation compared to those 35 
with HA and regular cycles and also those without HA and with regular cycles (p<0.05 for all). 36 
Compared to T1D women without PCOS, the 18% of T1D women who had PCOS were younger 37 
with lower BMI, an older age of menarche, and were more likely to have a positive family history 38 
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of PCOS (p<0.05 for all). Androgen levels did not differ between women with T1D and PCOS 39 
compared to BMI-matched non-diabetic women with PCOS, but androstenedione levels were 40 
greater in T1D women with PCOS compared to obese women with PCOS (p<0.05). 41 
Limitations, reasons for caution: Relatively small subgroups of patients were studied, 42 
reducing the power to detect small differences. Free testosterone levels were not measured 43 
using equilibrium dialysis, and were not calculated – commonly used formulae have not been 44 
validated in T1D. 45 
Wider implications of the findings: Androstenedione is a sensitive biochemical marker of 46 
clinical hyperandrogenism and PCOS in T1D. T1D women with PCOS are leaner than those 47 
without PCOS but are more likely to have a family history of PCOS. Women with T1D and 48 
PCOS have a similar biochemical phenotype to lean non-diabetic women with PCOS but differ 49 
from obese women with PCOS. The mechanisms underlying PCOS in T1D and its clinical 50 
significance require further investigation. 51 
Study funding/competing interest(s): The study was part-funded by the Meath Foundation. 52 
The authors have no competing interests. 53 
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Introduction 58 
Clinical hyperandrogenism (HA) and polycystic ovary syndrome (PCOS) commonly occur in 59 
reproductive-age women with Type 1 diabetes (T1D) (Codner, et al., 2007, Escobar-Morreale, 60 
et al., 2000, Miyoshi, et al., 2013, Zachurzok, et al., 2013). A recent meta-analysis has reported 61 
24% prevalence of PCOS, 25% of HA, 25% of hirsutism, and 24% of menstrual dysfunction 62 
(Escobar-Morreale, et al., 2016) in such women. These high rates of androgen excess are 63 
probably due to increased systemic insulin levels, which result from subcutaneous injection in 64 
contrast to the physiologic situation in which insulin is released into the portal circulation. These 65 
observations are potentially important because of reproductive, gynecologic and cosmetic 66 
symptoms, and also because it has yet to be established whether HA or PCOS status 67 
influences insulin sensitivity and/ or the significant burden of atherosclerotic disease in T1D.  68 
To date measurement of androgens in all studies that have addressed HA and PCOS in T1D 69 
has been carried out using immunoassays. Direct immunoassays have been shown to 70 
overestimate testosterone concentrations, particularly in women, who have much lower 71 
androgen concentrations compared to men, and use of these assays has been demonstrated to 72 
result in frequent misclassification of HA and PCOS status in women without diabetes (Bhasin, 73 
et al., 2008, Rosner, et al., 2007, Tosi, et al., 2016). Although organic solvent extraction and/or 74 
gas chromatography steps prior to immunoassay analysis can improve their sensitivity and 75 
specificity, these assays still require proper validation. Liquid chromatography-tandem mass 76 
spectrometry (LC-MS/MS) is a highly accurate method when properly validated and offers the 77 
advantage of measuring multiple steroids in a sample, and hence has been proposed as a “best 78 
prospect for gold standard” of testosterone measurement in the Endocrine Society Position 79 
Statement (Rosner, et al., 2007)  80 
Using LC-MS/MS measurement of androgens, this study was designed to evaluate HA and 81 
PCOS in reproductive-age women with T1D. The specific aims were to (1) compare androgen 82 
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profiles between women with and without T1D; (2) determine how androgen levels relate to 83 
clinical evidence of hyperandrogenism and PCOS in T1D; (3) further characterise PCOS in T1D 84 
with regard to clinical characteristics and androgen profile. 85 
86 
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Materials and Methods 87 
Study design and subjects 88 
To address the research questions listed above, the following analyses were carried out: 89 
1) A cross-sectional comparison of androgen levels in women with T1D compared to BMI- 90 
and age-matched healthy control women.  91 
2) A comparison of androgen levels between T1D women with clinical hyperandrogenism 92 
and anovulatory cycles, those with clinical hyperandrogenism but regular menstrual 93 
cycles, and those without clinical hyperandrogenism. 94 
3) Further characterization of PCOS in T1D with regard to clinical characteristics and 95 
androgen profile through: 96 
a. Determination of the prevalence of PCOS (NIH) criteria in T1D, and what 97 
characteristics distinguish them from T1D women without PCOS. 98 
b. Comparison of clinical and biochemical variables between women with T1D and 99 
PCOS, and non-diabetic women with PCOS. 100 
 101 
Subjects 102 
For each analysis, subjects were selected from three groups of reproductive-age women; 103 
women with T1D (n=87), non-diabetic women without PCOS (n=101) and non-diabetic women 104 
with PCOS (n= 97).  105 
Women with T1D were recruited from the Diabetes Database in Tallaght Hospital, Dublin, 106 
Ireland. Of a total patient population of 1109 with T1D, 354 were women between the ages of 18 107 
and 45 years. There were no differences in age (28.7±6.1 vs. 28.0 ±6.6 years), BMI (25.4±4.4 108 
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vs. 25.8±4.6 kg/m2) or haemoglobin A1c (HbA1c) (8.7±1.5 vs. 8.4±1.8 %) between those who 109 
took part in the study and those who did not.  110 
All eligible women were contacted either by phone or at the time of their scheduled clinic visit. 111 
Subjects were excluded if they were non-Caucasian, pregnant, or lactating; had a BMI less than 112 
18 or greater than 55 kg/m2; had a recent illness or any chronic illness likely to influence results; 113 
or were taking any medications likely to influence the results including hormonal contraception, 114 
antihypertensive, lipid-lowering medications, antiplatelet agents, anti-inflammatory agents, or 115 
nonprescription agents. Those with normal menstrual cycles were studied in the follicular phase.  116 
The control group was comprised of normal volunteers on no medications recruited from the 117 
general population. The recruitment of normal volunteers was done via advertisement in the 118 
study hospital, local schools and community centres. All normal subjects were eumenorrheic 119 
with testosterone levels within the normal female range and were studied in the follicular phase 120 
of the menstrual cycle.  121 
Women with PCOS who met the eligibility criteria were recruited by the study physician from the 122 
Endocrinology outpatient clinics in the Adelaide and Meath Hospital, Tallaght, Dublin. PCOS 123 
was defined according to the NIH criteria as chronic oligomenorrhea (fewer than nine menstrual 124 
periods per year) and clinical and/ or biochemical evidence of hyperandrogenism, in the 125 
absence of other disorders causing the same phenotype (Zawadzki JK, 1992). However, for the 126 
purposes of the current study, we only included those who had clinical hyperandrogenism. 127 
Clinical criteria included hirsutism with Ferriman-Gallwey score greater than 9, acne, or male 128 
pattern alopecia; biochemical criteria included total testosterone, androstenedione, 129 
or dehydroepiandrosterone sulphate (DHEAS) greater than the laboratory reference 130 
range.  Serum thyroid-stimulating hormone (TSH), free thyroxine, prolactin, LH, FSH, estradiol 131 
and 17-hydroxyprogesterone were measured in all PCOS subjects to exclude other disorders.  132 
To compare T1D women with non-diabetic women, subjects were pair-matched for age and for 133 
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BMI (Table I). The 87 women with T1D were then subdivided into 3 groups according to their 134 
clinical phenotypes: those with T1D and PCOS (clinical hyperandrogenism and anovulatory 135 
cycles) according to the NIH criteria (T1D-PCOS); those with clinical hyperandrogenism 136 
(hirsutism with a Ferriman-Gallwey score greater than 9, acne, or male pattern alopecia) but 137 
regular cycles (T1D-HA), and those with no clinical features (T1D-No CF). The 16 women with 138 
T1D-PCOS were also compared to 16 non-diabetic women with PCOS matched for age and 139 
BMI, and 16 obese non-diabetic women with PCOS matched for age.  140 
Ethical Approval  141 
All study subjects gave their written signed consent to the study, which was approved by the 142 
Research Ethics Committee of the Adelaide and Meath Hospital and St. James’ Hospital 143 
(Dublin, Ireland). 144 
Measurement of anthropological data and baseline characteristics 145 
All subjects were studied after a 12-h fast and having avoided excessive exercise and alcohol 146 
for the previous 24 hours. They underwent estimation of body composition using auxological 147 
methods. Height (measured with a Harpenden stadiometer) and weight were measured in a 148 
hospital gown. Waist circumference (WC) and hip circumference were measured with a non-149 
distensible flexible tape measure at the waist and hip. Each participant completed a health and 150 
lifestyle questionnaire, which included reproductive history, smoking history, and alcohol 151 
consumption.  152 
Laboratory methods 153 
Glucose was measured by an enzymatic (hexokinase) method on the Roche P Module (Roche, 154 
Stockholm, Sweden); insulin was measured by electrochemiluminescense immunoassay on the 155 
Roche E Module; eGDR, (estimation of the glucose disposal rate, a validated measure of insulin 156 
sensitivity in T1D was calculated as previously described (Williams, et al., 2000) in T1D women 157 
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only. Sex-hormone binding globulin (SHBG), estradiol, thyroid stimulating hormone (TSH), free 158 
thyroxine (FT4), prolactin, and cortisol were measured by standard chemiluminescence 159 
immunoassays (CVs <5% for all).  160 
Additional samples were centrifuged at 3000 rpm for 15 min at 4°C, and plasma and serum was 161 
stored at −80°C until the end of the study. They were then transported on dry ice by courier 162 
delivery to the Institute of Metabolism and Systems Research (IMSR), University of Birmingham, 163 
Edgbaston, Birmingham. Using previously described techniques (O'Reilly, et al., 2014), serum 164 
testosterone, androstenedione, dehydroepiandrosterone (DHEA) and dehydroepiandrosterone 165 
sulfate (DHEAS) were measured using a Waters Xevo mass spectrometer with Acquity uPLC 166 
system (Waters Ltd, Elstree, UK). LC/MS-MS conditions were an electrospray ionization source 167 
with capillary voltage 4.0 kV, a source temperature of 150°C, and a desolvation temperature of 168 
500°C. Serum steroid oxime analysis (Kushnir, et al., 2010) was used for the measurement of 169 
testosterone, androtenedione, and DHEA and carried out in positive mode, whereas the 170 
measurement of serum DHEAS was performed in negative mode. Testosterone, 171 
androstenedione, and DHEA were extracted from 200 μL serum via liquid-liquid extraction using 172 
1 mL tert-butyl-methyl-ether followed by derivatization into steroid oximes using 100 μL 173 
derivatization mixture (0.16 g hydroxylamine in 8 mL pyridine). For protein precipitation and 174 
extraction of DHEAS, 20 μL ZnSO4, 0.1 mM, and 100 μL acetonitrile were added to 20 μL 175 
serum before evaporation under constant nitrogen flow (Chadwick, et al., 2005). All steroids 176 
were separated using an optimized gradient system consisting of methanol with 0.1% formic 177 
acid and quantified referring to a linear calibration series with appropriate internal standards. 178 
Each steroid was identified by matching retention times and two mass transitions in comparison 179 
with a deuterated reference compound. The information regarding the precision for each 180 
androgen assay has been previously described (Buttler, et al., 2015, O'Reilly, et al., 2017) and 181 
is shown in detail in Supplementary Table S1.  182 
 183 
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Statistical analysis 184 
Statistical analysis was performed using Graph Pad Prism version 7.00, GraphPad Software, La 185 
Jolla California USA, www.graphpad.com 186 
 Results are presented as median and interquartile range (IQR) unless otherwise specified. 187 
Statistical analysis of clinical characteristics was made using Student’s t-test or Mann–Whitney 188 
U test for independent samples. One-Way ANOVA was used to analyze between group 189 
differences when more than 2 groups were reviewed, and the Kruskal-Wallis test was used for 190 
post hoc analysis. A p value <0.05 was considered significant. Graphical representation of data 191 
excluded any results 2 standard deviation above the mean, but all results were used in the 192 
analysis. 193 
194 
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Results 195 
Comparison of androgen levels in women with T1D compared to BMI and age-matched healthy 196 
control women 197 
32 women with T1D were compared to 32 BMI- and age-matched healthy control women.  198 
Baseline characteristics are shown in Table I and androgen levels in Figure 1. There were no 199 
significant differences in waist-to-hip ratio (WHR) between the two groups (Table I). There were 200 
no significant differences in testosterone, androstenedione, SHBG, DHEAS or DHEA between 201 
the two groups. Compared to non-diabetic women, DHEA/ DHEAS ratio was significantly lower 202 
(p <0.05) in women with T1D (Figure 1).  203 
Comparison of androgen levels between sub-groups of women with T1D 204 
Baseline characteristics are shown in Table II and androgen levels in Figure 2. Testosterone 205 
levels were greater (p <0.05) in T1D-PCOS compared to T1D-No CF. Androstenedione levels 206 
were greater (p <0.005) in T1D-PCOS compared to T1D-HA and T1D-no CF. No between-207 
group changes were observed in SHBG, DHEAS, DHEA or DHEA/ DHEAS ratio. 208 
Characterisation of PCOS in T1D with regard to clinical characteristics and androgen profile. 209 
a) Determination of the prevalence of PCOS (NIH) criteria in T1D, and what characteristics 210 
distinguish them from T1D women without PCOS  211 
The prevalence of PCOS in women with T1D was 18% (16/ 87). T1D-PCOS women compared 212 
to those without PCOS were younger (26.5 vs. 29.0 years) and had lower BMI (23.4 vs. 25.3 213 
kg/m2). T1D-PCOS women had an older age of menarche (13.0 vs. 12.5 years, p=0.024), and 214 
were more likely (12.5% vs. 2.8 %) to have a positive family history of PCOS.  215 
b) Comparison of androgens between women T1D- PCOS women, BMI-matched non-diabetic 216 
women with PCOS and obese non-diabetic women with PCOS 217 
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Demographic variables are shown in Table III and androgen levels in Figure 3. Compared to 218 
obese women with PCOS, androstenedione levels were greater (p <0.05) in T1D-PCOS 219 
women. SHBG levels were greater in T1D-PCOS women compared to obese non-diabetic 220 
women with PCOS. No other differences were observed between groups. 221 
 222 
223 
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Discussion 224 
To our knowledge this is the first study using LC-MS/MS to report androgen levels in 225 
reproductive-age women with T1D. Previous studies (Codner, et al., 2007, Escobar-Morreale, et 226 
al., 2000, Escobar-Morreale, et al., 2016, Miyoshi, et al., 2013, Zachurzok, et al., 2013) have 227 
used immunoassay techniques which can lack sensitivity and specificity, particularly at the 228 
relatively low concentrations of androgens observed in women (Tosi, et al., 2016). Among 229 
women with T1D, only testosterone and androstenedione helped discriminate between T1D-230 
PCOS and those with T1D-No CF, androstenedione proving more sensitive as it also 231 
discriminated between those with T1D-HA and those with T1D-PCOS. Women with T1D- PCOS 232 
were younger with lower BMI, had an older age of menarche, and were more likely to have a 233 
family history of PCOS than those without PCOS. Androgen levels did not differ between 234 
women with T1D- PCOS compared to BMI-matched non-diabetic women with PCOS, but 235 
androstenedione levels were greater in T1D- PCOS compared to obese non-diabetic women 236 
with PCOS. 237 
Clinical HA was observed in 49% of women with T1D, consistent with most previous studies 238 
(Escobar-Morreale, et al., 2016), while anovulatory cycles were observed in 30%. Eighteen 239 
percent had both and would thus meet NIH criteria for diagnosis of PCOS. Previous studies in 240 
non-diabetic women with PCOS demonstrated androstenedione (O'Reilly, et al., 2014) total 241 
testosterone/ dihydrotestosterone ratio (Munzker, et al., 2015), estrone (Stener-Victorin, et al., 242 
2010) and 11-oxygenated androgens (O'Reilly, et al., 2017) as the most sensitive markers of 243 
androgen excess. In the current study, among the variables studied, androstenedione proved to 244 
be the most sensitive biochemical marker of PCOS diagnosis, levels being greater in T1D-245 
PCOS compared to those with T1D-HA or T1D-No CF. Androstenedione levels also 246 
differentiated between T1D-PCOS women, and obese non-diabetic women with PCOS 247 
suggesting that it is potentially a useful clinical androgen measurement in T1D. We did not 248 
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measure dihydrotestosterone, estrone or 11-oxygenated androgens and therefore cannot 249 
compare the usefulness of these variables with androstenedione. 250 
Although absolute levels of DHEA-OX and DHEAS did not differ between women with T1D and 251 
healthy controls, a lower DHEA/ DHEAS ratio was observed among T1D subjects implying 252 
increased inactivation of DHEA by sulfation in the adrenal cortex and in the liver. This effect is 253 
potentially explained by systemic hyperinsulinemia, which is characteristic of T1D. Systemic 254 
hyperinsulinemia is generally considered to play a role in increasing active androgen burden in 255 
the circulation through direct effects on the ovary and adipose tissue (O'Reilly, et al., 2017, 256 
O'Reilly, et al., 2014); it could therefore be hypothesized that enhanced inactivation of DHEA to 257 
DHEAS, resulting in a lower DHEA/ DHEAS ratio, is a compensatory mechanism to remove 258 
active androgens from the circulation in patients with T1D.  259 
T1D women with PCOS were younger and of lower BMI than those without PCOS. Indices of 260 
insulin resistance including daily insulin dose and eGDR, a validated index of insulin sensitivity 261 
in T1D (Williams, et al., 2000) did not differ between those with and without PCOS. A family 262 
history of PCOS was predictive of PCOS in T1D suggesting contribution of genes associated 263 
with PCOS to the development of the phenotype in T1D. Other than a marginally later age of 264 
menarche in those with PCOS, we did not find any other differences compared to those without 265 
PCOS. The androgen profile of women with T1D and PCOS did not differ from BMI-matched 266 
non-diabetic women with PCOS, although androstenedione levels were greater in the diabetic 267 
PCOS compared to obese non-diabetic women with PCOS.  It appears therefore that PCOS in 268 
T1D is a similar condition to lean PCOS, but potentially differs from the more common 269 
phenotype of PCOS in obese women.  270 
Testosterone circulates bound to SHBG and albumins and only free, unbound testosterone 271 
exerts biological effect. A limitation of this study is the absence of data for free testosterone 272 
levels. This is important as substantially higher SHBG levels in women with T1D (probably due 273 
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to low insulin levels in the portal circulation (Yki-Jarvinen, et al., 1995) compared to non-diabetic 274 
women potentially result in lower free testosterone levels. To confidently understand this effect, 275 
however, it would be necessary to measure free testosterone using the gold standard technique 276 
of equilibrium dialysis (Vermeulen, et al., 1999). While free testosterone is often calculated, 277 
there are conflicting reports as to how well this correlates with measured free testosterone, 278 
(Zakharov, et al., 2015) (Hackbarth, et al., 2011, Ly, et al., 2010, Salameh, et al., 2010) and 279 
importantly there is no data to support the validity of this estimation in T1D, where particularly 280 
high levels of SHBG would potentially influence calculated values.  281 
In summary, our findings have helped further characterize HA and PCOS in women with T1D. 282 
Androstenedione appears to be the most discriminatory biochemical marker as it differs 283 
between T1D women with and without HA, and between lean (PCOS and non-diabetic) and 284 
obese women with PCOS. The biochemical phenotype of PCOS in T1D is similar to that in lean 285 
non-diabetic women with PCOS, and is more likely to occur when there is a family history of 286 
PCOS. The clinical relevance of PCOS and HA in T1D is not known but future studies aimed at 287 
determining whether they contribute cardio-metabolic abnormalities are now warranted. 288 
 289 
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Figure Legends 397 
Figure 1. Comparison of androgen levels in women with Type 1 diabetes (T1D) and non-398 
diabetic women (* p< 0.05). Horizontal lines represent median with interquartile range. 399 
 400 
Figure 2. Comparison of androgen levels between T1D women with clinical hyperandrogenism 401 
and anovulatory cycles (T1D-PCOS), those with clinical hyperandrogenism but regular cycles 402 
(T1D-HA) and those without clinical features (T1D-No CF) (* p< 0.05 ** p<0.005 *** p<0.0005). 403 
Horizontal lines represent median with interquartile range. 404 
 405 
Figure 3. Comparison of androgen levels in three different groups of women with PCOS : T1DM 406 
and PCOS (T1D-P), BMI-matched women with PCOS (Lean-P) and overweight women with 407 
PCOS (Obese-P) (* p<0.05, ** p<0.005, *** p<0.0005). Horizontal lines represent median with 408 
interquartile range. 409 
